Efficacy and Safety
Tumors, tumor, Tumor
DISEASE PROGRESSION, TUMOR, ADVERSE EVENT, TUMOR, ADVERSE EVENT, TUMORS
Tumor assessment and response to anlotinib therapy were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Tumor responses were assessed by local radiological review. All sites of tumor lesions were investigated using computed tomography at baseline within 3 weeks of enrollment before initiating therapy, then every 6 weeks until disease progression. Physical examination, blood cell counts, and blood biochemistry were carried out at baseline, on day 1 of each cycle. Adverse events were recorded according to Common Terminology Criteria for Adverse Events, version 4.0.